Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD31 immunoreactivity in carcinomas and mesotheliomas

B R De Young1, H F Frierson, M N Ly

  • 1Department of Pathology, Ohio State University Medical Center, Columbus 43210, USA.

American Journal of Clinical Pathology
|September 5, 1998
PubMed
Summary

CD31 is a reliable marker for endothelial differentiation. This study found rare CD31 immunoreactivity in carcinomas and mesotheliomas, supporting its specificity for vascular tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRCA2 alteration is important in clear cell carcinoma of the ovary.

Clinical genetics·2009
Same author

Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2000
Same author

MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells.

Cancer·1999
Same author

MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma.

Cancer·1999
Same author

Altered expression of gamma-glutamyl transpeptidase in human tumors.

Human pathology·1999
Same author

Altered localization of E-cadherin and alpha-catenin in rat esophageal tumors.

International journal of oncology·1998

Area of Science:

  • Oncology
  • Pathology
  • Immunohistochemistry

Background:

  • CD31 is a well-established marker for endothelial differentiation in soft tissue neoplasms.
  • Previous research has extensively compared CD31 with other endothelial markers.
  • The reactivity of CD31 in carcinomas and mesotheliomas remains incompletely understood.

Purpose of the Study:

  • To investigate the expression of CD31 in a broad spectrum of neoplasms, specifically focusing on carcinomas and mesotheliomas.
  • To evaluate the diagnostic utility of CD31 as an endothelial marker in challenging cases.

Main Methods:

  • Applied anti-CD31 (JC70/A) immunohistochemistry to 290 characterized neoplasms.
  • Utilized a modified avidin-biotin-peroxidase complex technique with microwave epitope retrieval.

Related Experiment Videos

  • Analyzed the pattern and frequency of CD31 immunoreactivity.

    • Main Results:

    • CD31 immunoreactivity was observed in only seven carcinomas (2 papillary thyroid, 2 mucoepidermoid salivary gland, 1 cutaneous adnexal, 1 cutaneous squamous cell, 1 esophageal squamous cell).
    • The observed immunoreactivity was plasmalemmal-based.
    • The vast majority of neoplasms (283 out of 290) were negative for CD31.

    Conclusions:

    • Anti-CD31 immunostaining is rare in carcinomas and mesotheliomas.
    • These findings reinforce CD31's reliability as a specific marker of endothelial differentiation.
    • CD31 should be considered in immunohistochemical panels for diagnosing vascular tumors.